Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 434 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016', provides an overview of the Recurrent Glioblastoma Multiforme (GBM) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Recurrent Glioblastoma Multiforme (GBM)
- The report reviews pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Recurrent Glioblastoma Multiforme (GBM) therapeutics and enlists all their major and minor projects
- The report assesses Recurrent Glioblastoma Multiforme (GBM) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Recurrent Glioblastoma Multiforme (GBM)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Recurrent Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Content 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Recurrent Glioblastoma Multiforme (GBM) Overview 9
Therapeutics Development 10
Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Overview 10
Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis 11
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 12
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 15
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Recurrent Glioblastoma Multiforme (GBM) - Products under Development by Companies 19
Recurrent Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 23
Recurrent Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 24
AbbVie Inc. 24
Agenus, Inc. 25
Amgen Inc. 26
AngioChem Inc. 27
Apogenix GmbH 28
AstraZeneca Plc 29
Axelar AB 30
BeiGene, Ltd. 31
Boehringer Ingelheim GmbH 32
Boston Biomedical, Inc. 33
Bristol-Myers Squibb Company 34
Cantex Pharmaceuticals, Inc. 35
Cavion LLC 36
Celldex Therapeutics, Inc. 37
Coherus BioSciences, Inc. 38
Cortice Biosciences, Inc. 39
Eisai Co., Ltd. 40
Eli Lilly and Company 41
EnGeneIC Ltd 42
ERC Belgium SA 43
GenSpera, Inc. 44
Genzyme Corporation 45
GW Pharmaceuticals Plc 46
ImmunoCellular Therapeutics, Ltd. 47
Karyopharm Therapeutics, Inc. 48
Les Laboratoires Servier SAS 49
Medicenna Therapeutics, Inc. 50
Merck & Co., Inc. 51
Novartis AG 52
Ono Pharmaceutical Co., Ltd. 53
Oryx GmbH & Co. KG 54
Pfizer Inc. 55
Stemline Therapeutics, Inc. 56
Threshold Pharmaceuticals, Inc. 57
Tocagen Inc. 58
TRACON Pharmaceuticals, Inc. 59
Vascular Biogenics Ltd. 60
Vaximm AG 61
Virttu Biologics Limited 62
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics Assessment 63
Assessment by Monotherapy Products 63
Assessment by Combination Products 64
Assessment by Target 65
Assessment by Mechanism of Action 69
Assessment by Route of Administration 72
Assessment by Molecule Type 74
Drug Profiles 76
(GWP-42002 + GWP-42003) - Drug Profile 76
abemaciclib - Drug Profile 77
acalabrutinib - Drug Profile 79
afatinib dimaleate - Drug Profile 82
AMG-595 - Drug Profile 87
asinercept - Drug Profile 89
AU-101 - Drug Profile 91
AU-105 - Drug Profile 92
axitinib - Drug Profile 93
AXL-1717 - Drug Profile 97
AZD-7451 - Drug Profile 99
bevacizumab biosimilar - Drug Profile 100
BGB-290 - Drug Profile 101
bosutinib - Drug Profile 103
buparlisib hydrochloride - Drug Profile 106
capmatinib - Drug Profile 110
Cellular Immunotherapy for Recurrent Glioblastoma Multiforme - Drug Profile 113
Cellular Immunotherapy to Target Interleukein 13 Receptor Alpha-2 for Acute Myelocytic Leukemia and Glioblastoma Multiforme - Drug Profile 114
CX-02 - Drug Profile 115
dacomitinib - Drug Profile 116
dasatinib - Drug Profile 119
depatuxizumab mafodotin - Drug Profile 122
DNX-2401 - Drug Profile 124
ERC-1671 - Drug Profile 127
evofosfamide - Drug Profile 129
flucytosine ER + vocimagene amiretrorepvec - Drug Profile 137
G-200 - Drug Profile 140
galunisertib - Drug Profile 142
golvatinib + lenvatinib - Drug Profile 144
golvatinib tartrate - Drug Profile 146
HSV-1716 - Drug Profile 148
ICT-121 - Drug Profile 151
infigratinib - Drug Profile 153
lenvatinib mesylate - Drug Profile 154
lonafarnib - Drug Profile 160
MDNA-55 - Drug Profile 162
mibefradil dihydrochloride - Drug Profile 163
mipsagargin - Drug Profile 165
nabiximols - Drug Profile 167
napabucasin - Drug Profile 171
NEO-100 - Drug Profile 174
nilotinib - Drug Profile 176
nivolumab - Drug Profile 180
ofranergene obadenovec - Drug Profile 188
ONC-201 - Drug Profile 190
Oncolytic Virus for Oncology - Drug Profile 193
Oncolytic Virus to Target Carcinoembryonic Antigen for Oncology - Drug Profile 194
Oncolytic Virus to Target IL-12 for Oncology - Drug Profile 196
OS-2966 - Drug Profile 197
p28 - Drug Profile 198
paclitaxel trevatide - Drug Profile 200
Parvoryx - Drug Profile 202
pazopanib hydrochloride - Drug Profile 203
pembrolizumab - Drug Profile 209
ramucirumab - Drug Profile 219
rilotumumab - Drug Profile 225
rindopepimut - Drug Profile 227
S-49076 - Drug Profile 229
selinexor - Drug Profile 230
SGT-53 - Drug Profile 236
SL-701 - Drug Profile 238
sonidegib phosphate - Drug Profile 240
TPI-287 - Drug Profile 244
TRC-102 - Drug Profile 247
trebananib - Drug Profile 249
vandetanib - Drug Profile 252
VEDVDox - Drug Profile 258
vorinostat - Drug Profile 259
VXM-01 - Drug Profile 263
Recurrent Glioblastoma Multiforme (GBM) - Recent Pipeline Updates 265
Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects 415
Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products 417
Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones 418
Featured News & Press Releases 418
Appendix 428
Methodology 428
Coverage 428
Secondary Research 428
Primary Research 428
Expert Panel Validation 428
Contact Us 428
Disclaimer 429

List of Tables

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H1 2016 15
Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Number of Products under Development by Companies, H1 2016 (Contd..1) 18
Number of Products under Development by Companies, H1 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2016 20
Comparative Analysis by Late Stage Development, H1 2016 21
Comparative Analysis by Clinical Stage Development, H1 2016 22
Comparative Analysis by Early Stage Development, H1 2016 23
Products under Development by Companies, H1 2016 24
Products under Development by Companies, H1 2016 (Contd..1) 25
Products under Development by Companies, H1 2016 (Contd..2) 26
Products under Development by Companies, H1 2016 (Contd..3) 27
Products under Investigation by Universities/Institutes, H1 2016 28
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc., H1 2016 29
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H1 2016 30
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H1 2016 31
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc., H1 2016 32
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H1 2016 33
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca Plc, H1 2016 34
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H1 2016 35
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by BeiGene, Ltd., H1 2016 36
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 37
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical, Inc., H1 2016 38
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H1 2016 39
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals, Inc., H1 2016 40
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H1 2016 41
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics, Inc., H1 2016 42
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences, Inc., H1 2016 43
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences, Inc., H1 2016 44
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co., Ltd., H1 2016 45
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H1 2016 46
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H1 2016 47
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H1 2016 48
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GenSpera, Inc., H1 2016 49
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Genzyme Corporation, H1 2016 50
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H1 2016 51
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2016 52
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 53
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H1 2016 54
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics, Inc., H1 2016 55
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co., Inc., H1 2016 56
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H1 2016 57
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 58
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co. KG, H1 2016 59
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H1 2016 60
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics, Inc., H1 2016 61
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 62
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc., H1 2016 63
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016 64
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd., H1 2016 65
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H1 2016 66
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Limited, H1 2016 67
Assessment by Monotherapy Products, H1 2016 68
Assessment by Combination Products, H1 2016 69
Number of Products by Stage and Target, H1 2016 71
Number of Products by Stage and Mechanism of Action, H1 2016 75
Number of Products by Stage and Route of Administration, H1 2016 78
Number of Products by Stage and Molecule Type, H1 2016 80
Recurrent Glioblastoma Multiforme (GBM) Therapeutics - Recent Pipeline Updates, H1 2016 270
Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2016 420
Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H1 2016 421
Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products, H1 2016 422